Melynda Barnes, M.D. is the Chief Medical Officer at Ro. She believes "more people will gain access to GLP-1 inhibitors" in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Melynda Barnes, M.D., said:
“Telehealth will be better than in-person care for certain chronic conditions. Telehealth offers a scalable solution to one of America’s most plaguing health challenges: obesity.
In 2024, more people will also access care for glucagon-like peptide 1 (GLP-1) inhibitors through direct-to-patient care than in-person providers. We’ll see more people turning to direct-to-patient care as new, more efficacious GLP-1s are introduced.
Employers that offer GLP-1s will poach and retain top talent. Employers that take this risk will reap the benefit of employees incentivized to stay. Survey data even show 44% of people would change jobs to access obesity treatment, and 51% would stay at a job they didn’t like to retain access to obesity treatment.”
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More